File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: A Randomized Controlled Trial Of Concurrent UFT/Radiation And Adjuvant Chemotherapy For Loco-regionally Advanced Non-metastatic Nasopharyngeal Carcinoma

TitleA Randomized Controlled Trial Of Concurrent UFT/Radiation And Adjuvant Chemotherapy For Loco-regionally Advanced Non-metastatic Nasopharyngeal Carcinoma
Authors
Issue Date2002
PublisherJohn Wiley & Sons, Inc.
Citation
The 18th UICC International Cancer Congress, Oslo, Norway, 30 June - 5 July 2002. In International Journal of Cancer, 2002, v. 100 n. S13, p. 79 Abstract no. O30 How to Cite?
AbstractBackground of the study: There have been many attempts tocombine chemotherapy (CT) and radiotherapy (RT) in treatment ofnasopharyngeal carcinoma (NPC), but improvement in tumor con-trol over standard RT was demonstrated only recently by theInternational Nasopharyngeal Carcinoma Study and the Head andNeck Intergroup. Methods and material: Patients with newly di-agnosed non-metastatic NPC with Ho’s stage T3, or N2-N3 dis-ease, or any lymph node „d4 cm were recruited. Patients were firstrandomized to receive UFT 200mg 3 times per day during wholecourse of RT or RT only, and they were also further randomizedto receive AC or no AC after RT. AC consisted of alternating PF (cisplatin 100mg/m2 D1 and 5-FU 1g/m2 D1-3) and VBM (vin-cristine 2mg, bleomycin 30mg and methotrexate 250mg/m2, all onD1) for total of 6 cycles. Thus, there were 4 treatment groups: a.RT alone, b. RT with concurrent UFT, c. RT and AC, d. RT withconcurrent UFT and then AC. For the analysis on efficacy ofconcurrent chemoradiation (i.e. no UFT vs. UFT), groups a and cwere compared with groups b and d. For the analysis on efficacyof AC (i.e. no AC vs. AC), groups a and b were compared withgroups c and d. Results: One hundred fifty-seven patients, atmedian follow up of 34 months, were included in this analysis.There was no significant difference in number of patients andprognostic factors between the groups. The 3 years failure-freesurvival (FFS) of the 4 groups were respectively 54.5%, 69.6%,51.1% and 73.3%. Patients on concurrent chemoradiation withUFT fared significantly better than patients on RT only (3 yearsFFS 71.4% vs. 52.9%, p ⫽ 0.019), but there was no significantdifference in 3 years overall survival (83.9% vs. 75.9%, p ⫽ 0.29).There was no significant difference in outcome for patients withand without AC (3 years FFS: 62.9% vs. 61.4%, p ⫽ 0.68).Conclusion: The results will be discussed.
Persistent Identifierhttp://hdl.handle.net/10722/105606
ISSN
2015 Impact Factor: 5.531
2015 SCImago Journal Rankings: 2.657

 

DC FieldValueLanguage
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorKwong, DLWen_HK
dc.contributor.authorAu, GKHen_HK
dc.contributor.authorChua, DTT-
dc.date.accessioned2010-09-25T22:41:10Z-
dc.date.available2010-09-25T22:41:10Z-
dc.date.issued2002en_HK
dc.identifier.citationThe 18th UICC International Cancer Congress, Oslo, Norway, 30 June - 5 July 2002. In International Journal of Cancer, 2002, v. 100 n. S13, p. 79 Abstract no. O30-
dc.identifier.issn0020-7136-
dc.identifier.urihttp://hdl.handle.net/10722/105606-
dc.description.abstractBackground of the study: There have been many attempts tocombine chemotherapy (CT) and radiotherapy (RT) in treatment ofnasopharyngeal carcinoma (NPC), but improvement in tumor con-trol over standard RT was demonstrated only recently by theInternational Nasopharyngeal Carcinoma Study and the Head andNeck Intergroup. Methods and material: Patients with newly di-agnosed non-metastatic NPC with Ho’s stage T3, or N2-N3 dis-ease, or any lymph node „d4 cm were recruited. Patients were firstrandomized to receive UFT 200mg 3 times per day during wholecourse of RT or RT only, and they were also further randomizedto receive AC or no AC after RT. AC consisted of alternating PF (cisplatin 100mg/m2 D1 and 5-FU 1g/m2 D1-3) and VBM (vin-cristine 2mg, bleomycin 30mg and methotrexate 250mg/m2, all onD1) for total of 6 cycles. Thus, there were 4 treatment groups: a.RT alone, b. RT with concurrent UFT, c. RT and AC, d. RT withconcurrent UFT and then AC. For the analysis on efficacy ofconcurrent chemoradiation (i.e. no UFT vs. UFT), groups a and cwere compared with groups b and d. For the analysis on efficacyof AC (i.e. no AC vs. AC), groups a and b were compared withgroups c and d. Results: One hundred fifty-seven patients, atmedian follow up of 34 months, were included in this analysis.There was no significant difference in number of patients andprognostic factors between the groups. The 3 years failure-freesurvival (FFS) of the 4 groups were respectively 54.5%, 69.6%,51.1% and 73.3%. Patients on concurrent chemoradiation withUFT fared significantly better than patients on RT only (3 yearsFFS 71.4% vs. 52.9%, p ⫽ 0.019), but there was no significantdifference in 3 years overall survival (83.9% vs. 75.9%, p ⫽ 0.29).There was no significant difference in outcome for patients withand without AC (3 years FFS: 62.9% vs. 61.4%, p ⫽ 0.68).Conclusion: The results will be discussed.-
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc.-
dc.relation.ispartofInternational Journal of Canceren_HK
dc.titleA Randomized Controlled Trial Of Concurrent UFT/Radiation And Adjuvant Chemotherapy For Loco-regionally Advanced Non-metastatic Nasopharyngeal Carcinomaen_HK
dc.typeConference_Paperen_HK
dc.identifier.emailSham, JST: jstsham@hku.hken_HK
dc.identifier.emailKwong, DLW: dlwkwong@hkucc.hku.hken_HK
dc.identifier.emailChua, DTT: danielchua@hksh.comen_HK
dc.identifier.authorityKwong, DLW=rp00414en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ijc.9998-
dc.identifier.hkuros82194en_HK
dc.identifier.hkuros72356-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats